PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group

Leukemia
M L LohChildren's Cancer Group

Abstract

The PTPN11 gene encodes SHP-2, a nonreceptor protein tyrosine phosphatase that relays signals from activated growth factor receptors to p21(ras) (Ras) and other signaling molecules. Somatic PTPN11 mutations are common in patients with juvenile myelomonocytic leukemia (JMML) and have been reported in some other hematologic malignancies. We analyzed specimens from 278 pediatric patients with acute myelogenous leukemia (AML) who were enrolled on Children's Cancer Group trials 2941 and 2961 for PTPN11 mutations. Missense mutations of PTPN11 were detected in 11 (4%) of these samples. None of these patients had mutations in NRAS; however, one patient had evidence of a FLT3 alteration. Four of the patients with PTPN11 mutations (36%) were boys with French-American-British (FAB) morphology M5 AML (P=0.012). Patients with mutations also presented with elevated white blood cell counts. There was no difference in clinical outcome for patients with and without PTPN11 mutations. These characteristics identify a subset of pediatric AML with PTPN11 mutations that share clinical and biologic features with JMML.

References

Oct 1, 1988·American Journal of Medical Genetics·D R WittJ G Hall
Sep 1, 1995·Journal of Medical Genetics·S KhanA Fryer
Nov 1, 1995·Pediatric Hematology and Oncology·J M JohannesR S Weening
Oct 1, 1996·Acta Paediatrica·A A MassaranoM Super
Nov 1, 1996·Molecular Medicine Today·P D EmanuelR P Castleberry
Jan 1, 1996·Rapid Communications in Mass Spectrometry : RCM·M G Qian, D M Lubman
Jun 1, 1997·The Journal of Pediatrics·B Bader-MeunierJ P Dommergues
Mar 10, 1998·Cell·P HofS E Shoelson
Mar 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E L SieversS A Feig
Apr 17, 1999·Journal of Pediatric Hematology/oncology·K J KlopfensteinF B Ruymann
Oct 19, 1999·Journal of Pediatric Hematology/oncology·G BisognoM Carli
Aug 15, 2002·Blood·D Gary Gilliland, James D Griffin
Apr 8, 2003·Journal of Pediatric Hematology/oncology·Andreas JungOliver Ehrt
May 20, 2003·Revista do Hospital das Clínicas·Débora R BertolaClaudette H Gonzalez
Dec 3, 2003·Blood·Mignon L LohKevin M Shannon
Dec 31, 2003·Proceedings of the National Academy of Sciences of the United States of America·Benjamin S BraunKevin M Shannon
Feb 18, 2004·The Journal of Clinical Investigation·Iris T ChanD Gary Gilliland

❮ Previous
Next ❯

Citations

Feb 21, 2008·Cancer Metastasis Reviews·Gordon ChanBenjamin G Neel
Aug 5, 2009·Proceedings of the National Academy of Sciences of the United States of America·Ina RadtkeJames R Downing
Mar 6, 2009·The Journal of Biological Chemistry·Xiangdong Zhou, Yehenew M Agazie
Apr 17, 2012·Current Opinion in Hematology·Sarah C Nabinger, Rebecca J Chan
Apr 7, 2007·Journal of Pediatric Hematology/oncology·Jeanie L Y Cheong, Martina H Moorkamp
Aug 30, 2005·Annual Review of Genomics and Human Genetics·Marco Tartaglia, Bruce D Gelb
Jul 22, 2010·Molecular Syndromology·M TartagliaB D Gelb
Jan 27, 2012·Development·Yvette LangdonFrank L Conlon
Sep 9, 2005·International Journal of Hematology·Hitoshi KiyoiKazutaka Ozekia
Aug 5, 2006·Pharmacogenomics·Eric KnocheTimothy A Graubert
Aug 16, 2013·Journal of Biochemistry·Norifumi WatanabeSeiichi Kitagawa
Dec 2, 2014·Pediatric Clinics of North America·Prakash SatwaniChristopher C Dvorak
Dec 14, 2011·Advances in Hematology·Xiaoling LiuCheng-Kui Qu
Oct 1, 2005·Leukemia & Lymphoma·Carmen BergomPeter J Newman
Sep 6, 2015·European Journal of Medical Genetics·Mylène TajanArmelle Yart
Jan 13, 2016·Proceedings of the National Academy of Sciences of the United States of America·Xia LiuCheng-Kui Qu
Oct 16, 2015·Proceedings of the National Academy of Sciences of the United States of America·Helen He ZhuGen-Sheng Feng
Feb 1, 2012·Seminars in Oncology·Hideki MuramatsuJaroslaw P Maciejewski
Jun 15, 2011·Bioorganic & Medicinal Chemistry Letters·Zhi-Hong YuZhong-Yin Zhang
Jul 9, 2014·Journal of Medicinal Chemistry·Li-Fan ZengZhong-Yin Zhang
Dec 17, 2015·The Journal of Experimental Medicine·Megan A HatlenStephen D Nimer
Dec 1, 2015·Nature Communications·Severa BundaMichael Ohh
Apr 22, 2005·British Journal of Haematology·Marco TartagliaAndrea Biondi
Aug 24, 2005·British Journal of Haematology·B F GoemansG J L Kaspers
Jul 23, 2009·Cancer Science·Takashi MatozakiHiroshi Ohnishi
May 13, 2008·Human Mutation·Yoko AokiYoichi Matsubara
Oct 21, 2010·Annals of the New York Academy of Sciences·Marco Tartaglia, Bruce D Gelb
May 4, 2011·Birth Defects Research. Part A, Clinical and Molecular Teratology·Erin KaltenbrunFrank L Conlon
Jun 7, 2005·Biochemical Pharmacology·Kriti Rakesh, Devendra K Agrawal
Apr 25, 2006·Cancer Genetics and Cytogenetics·Simone MartinelliMarco Tartaglia
Mar 15, 2006·Leukemia Research·Tomoko YamamotoSeiji Kojma
Aug 2, 2005·European Journal of Medical Genetics·Marco Tartaglia, Bruce D Gelb
Dec 3, 2011·Bioorganic & Medicinal Chemistry·Yantao HeZhong-Yin Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.